—
According to a new research report “Post-Traumatic Stress Disorder (PTSD) Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, PTSD currently exhibits a strong pipeline with 23 drug candidates.Browse Report Description at: https://www.psmarketresearch.com/market-analysis/ptsd-therapeutics-pipeline-analysis
The study analysed that the PTSD pipeline comprises of 23 drug candidates in different stages of development. PTSD is a neurological disorder that develops in people who have experienced a scary or a dangerous event. PTSD can occur in a person at any age. According to the National Center of PTSD, around seven to eight out of 100 individuals experience PTSD at some point in their lives. Most of the people recover from traumatic situation naturally, but those who continue to experience problems are diagnosed with PTSD. People with PTSD are used to feel frightened even when they are not in a dangerous situation. PTSD generally occurs more often in women than men. Various collaboration between educational institutes, associations, and pharma companies are driving the therapeutic pipeline of PTSD.
Significant growth in the therapeutic pipeline of PTSD is attributed to increasing collaboration between educational institutes, associations and pharma companies. Funds from the non-profit organizations have also been supporting the pipeline growth of PTSD therapeutics.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/ptsd-therapeutics-pipeline-analysis/report-sample
Some of the key players developing drugs for the treatment of PTSD include India Globalization Capital, Inc., Therapade Technologies LLC, Axim Biotechnologies, Inc. and others.
Contact Info:
Name: Abhishek
Email: Send Email
Organization: P&S Market Research
Address: 347, 5th Ave. #1402, New York City, NY - 10016
Phone: +1-888-778-7886
Website: https://www.psmarketresearch.com/
Release ID: 236384